Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cδ

This publication has 45 references indexed in Scilit:

• Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
  Blood, 2006
• Involvement of a Rho‐ROCK‐JNK pathway in arsenic trioxide‐induced apoptosis in chronic myelogenous leukemia cells
  FEBS Letters, 2006
• Proteasome inhibitors: antitumor effects and beyond
  Leukemia, 2006
• Pharmacologic inhibitors of extracellular signal‐regulated kinase (ERKs) and c‐Jun NH₂‐terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide‐induced apoptosis
  Journal of Cellular Physiology, 2006
• Proteasome inhibitor bortezomib for the treatment of multiple myeloma
  Leukemia, 2006
• Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia
  Clinical Cancer Research, 2006
• The biology of CML blast crisis
  Blood, 2004
• The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib
  Experimental Cell Research, 2004
• Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells
  Experimental & Molecular Medicine, 2003
• Clinical Experience of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
  The Oncologist, 2001